Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03751657 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 247
- Enrollment target
NCT03751657 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 247 participants.
The verdict
NCT03751657, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 247 participants
- Enrollment target
Study Summary
The study compares 2 medicines for people with type 2 diabetes: insulin 287 (a new medicine) and insulin glargine (a medicine doctors can already prescribe). The study doctors will test insulin 287 to see how well it works compared to insulin glargine. The study will also test if insulin 287 is safe. The study participants will either get insulin 287 or insulin glargine (100 units/mL) - which treatment the participants get is decided by chance. The participants will need to inject their selves every day about the same time. Once a week the participant will need to take 1 extra injection on the same day of the week. The participants will have 16 clinic visits and 14 phone calls with the study doctor. During the study, the doctors will ask you to: 1) measure your blood sugar every day with a blood glucose meter using a finger prick, 2) write down different information in a paper diary daily and return this to your doctor, 3) wear a medical device to measure your blood sugar all the time for 2 weeks 5 times during the study.
Interventions
- DRUG Metformin
- DRUG Insulin icodec
- DRUG Insulin glargine
- DRUG Placebo (insulin 287)
- DRUG Dipeptidyl peptidase-4 inhibitors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2020-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03751657
The ClinicalTrials.gov registry entry for NCT03751657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT03751657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03751657 about?
NCT03751657 is a clinical study titled "A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.". The study compares 2 medicines for people with type 2 diabetes: insulin 287 (a new medicine) and insulin glargine (a medicine doctors can already prescribe). The study doctors will test insulin 287 to see how well it works compared to insulin glargine. The study will also test if insulin 287 is safe...
What is the current status of trial NCT03751657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 247 participants. The study started on 2018-11-29. Estimated completion is 2020-01-17.
What interventions are being tested in trial NCT03751657?
The interventions under investigation include: Metformin (DRUG), Insulin icodec (DRUG), Insulin glargine (DRUG), Placebo (insulin 287) (DRUG), Dipeptidyl peptidase-4 inhibitors (DRUG).
Who is sponsoring clinical trial NCT03751657?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.